Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 21:16:6277-6284.
doi: 10.2147/IDR.S429706. eCollection 2023.

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder

Wan Miao  1 , Jinlin Guo  1 , Huifang Cheng  1 , Qianqian Zhao  1
Affiliations

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder

Wan Miao et al. Infect Drug Resist. .

Abstract

Purpose: Cefoperazone/sulbactam is a β-lactam/β-lactamase inhibitor combination effective against intra-abdominal, urinary tract, and respiratory infections. Although some studies have suggested that cefoperazone/sulbactam is associated with coagulation disorders, it remains debatable whether the combination of cefoperazone/sulbactam with tigecycline or valproic acid increases the risk of bleeding, as both drugs can lead to coagulation disorders. This study aimed to explore the risk factors of cefoperazone/sulbactam-induced coagulopathy.

Patients and methods: This was a single-center, retrospective, nested case-control study. The sample groups were derived from individuals registered at the Department of Neurosurgery, Shanxi Provincial People's Hospital. Propensity score matching (PSM) was used to adjust for demographic data. Conditional logistic regression was used to estimate the matched odds ratios representing the odds of cefoperazone/sulbactam-induced coagulopathy (CIC), and a receiver operating characteristic curve was used to determine the optimal cut-off conditions.

Results: After PSM, 155 and 56 patients were included in the control and case groups, respectively. Multivariate analysis revealed that advanced age, treatment duration, and total dose were independent risk factors of cefoperazone/sulbactam-induced coagulation disorders. Concomitant use of vitamin K was an independent protective factor against CIC. The optimal cut-off for the length of treatment was 5 d, and the cut-off for the total dose was 48 g.

Conclusion: Tigecycline and valproic acid were not associated with CIC. Advanced age and long treatment duration are risk factors for CIC. Supplementation with vitamin K during cefoperazone/sulbactam treatment was associated with a reduced risk.

Keywords: cefoperazone/sulbactam; coagulopathy; tigecycline; valproic acid.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Cohort exclusions and nested case-control design.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curve.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. doi:10.1128/CMR.00037-09 - DOI - PMC - PubMed
    1. Su J, Guo Q, Li Y, et al. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3176–3180. doi:10.1093/jac/dky323 - DOI - PubMed
    1. Xin X, Jian L, Xia X, et al. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013;12(1):38. doi:10.1186/1476-0711-12-38 - DOI - PMC - PubMed
    1. Greenberg RN, Reilly PM, Weinandt WJ, Bollinger M, Kennedy DJ. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation. Clin Ther. 1987;10(1):52–56. - PubMed
    1. Wong RS, Cheng G, Chan NP, Wong WS, Ng MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol. 2006;81(1):76. doi:10.1002/ajh.20449 - DOI - PubMed